Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Other Financing Activities
Financing cash flows not reported separately.
Helix BioPharma Corp.TSX: HBP.TO
Other Financing Activities · Q3 FY2026 · quarter ended Apr 2026
Other financing activities outflow grows to CA$3.67M
Q3 FY2026 other financing activities was CA$3.67M, compared with CA$0 a year earlier. Trailing-twelve-month other financing activities was CA$3.67M.
Context
- Other financing activities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other financing activities holds near CA$3.67M or moves back toward the trailing-twelve-month quarterly average of CA$918.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
CAD · from the cash flow
- Latest · FY2025
- 0 CAD
- Year-over-year change
- —
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 0 | — |
| FY2024 | 2024-07-31 | 0 | -100.0% |
| FY2023 | 2023-07-31 | 999K | -68.9% |
| FY2022 | 2022-07-31 | 3.21M | -9.8% |
| FY2021 | 2021-07-31 | 3.56M | — |
Other Financing Activities vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$15.56M CAD | +17722.0% | — | — | |
| LTM Apr 2026 | CA$3.67M CAD | — | — | — | |
| LTM Mar 2026 | $1.75M USD | +41.0% | +11.1% | 3.1% | |
MSCL.TOSatellos Bioscience Inc. | LTM Mar 2026 | $833.12K USD | — | — | — |
| LTM Apr 2026 | CA$27.02K CAD | -100.5% | — | — | |
| Peer median (excluding HBP.TO) | — | +41.0% | +11.1% | 3.1% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jul 2021 | FY2022 Jul 2022 | FY2023 Jul 2023 | FY2024 Jul 2024 | FY2025 Jul 2025 |
|---|---|---|---|---|---|
| Net Income | (8.04M) | (6.56M) | (6.29M) | (9.26M) | (5.21M) |
| Depreciation & Amortization | 199K | 12K | 13K | 14K | 10K |
| Deferred Income Tax | (2.22M) | 9K | 0 | 0 | 0 |
| Stock-Based Compensation | 664K | 425K | 570K | 3.52M | 0 |
| Change in Working Capital | (54K) | (892K) | 186K | 485K | 1.33M |
| Accounts Receivables | (173K) | 74K | 217K | 8K | (68K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 50K | (867K) | (106K) | 0 | 0 |
| Other Working Capital | 69K | (99K) | 75K | 477K | 1.4M |
| Other Non-Cash Items | 142K | 500K | (5K) | 31K | 31K |
| Operating Cash Flow | (9.3M) | (6.51M) | (5.53M) | (5.22M) | (3.83M) |
| Capital Expenditures | 0 | 0 | (10K) | (14K) | (2K) |
| Acquisitions (Net) | 2.02M | 0 | 5K | 0 | 19K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 2.02K | 0 | 5K | 0 | 0 |
| Investing Cash Flow | 2.02M | 0 | (5K) | (14K) | 17K |
| Debt Repayment | 3M | 0 | (2.06M) | 0 | 0 |
| Common Stock Issued | 3.56M | 2.99M | 4.15M | 5.51M | 2.8M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.56M | 3.21M | 999K | 0 | 0 |
| Financing Cash Flow | 6.56M | 6.21M | 3.09M | 5.51M | 2.8M |
| Effect of Forex Changes | 52K | (9K) | 0 | 0 | 0 |
| Net Change in Cash | (670K) | (313K) | (2.44M) | 273K | (1.02M) |
| Free Cash Flow | (9.3M) | (6.51M) | (5.54M) | (5.23M) | (3.83M) |
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.